CSL Ltd (ASX: CSL) shares have staged a remarkable comeback, surging 24% in just five trading days and around 40% over the past month.

Yet despite the explosive rally, the ASX biotech stock remains down about 3% year to date and 22% over the past 12 months.

So, has the market finally turned the corner or has the rally gone too far? Following last week’s earnings result, brokers have reassessed their forecasts. And their price targets reveal just how divided the experts are about where CSL shares could go next.

Could $200 really be on the cards?

Why are CSL shares on the rise?

The catalyst was CSL’s FY26 result, released last week Tuesday. At first glance, the numbers looked disastrous. CSL reported a US$2.6 billion net loss after tax.

But investors quickly looked beneath the headline figure. The loss included US$7.1 billion of pre-tax impairments and another US$799 million in restructuring costs, much of which was non-cash. Most of the impairments related to CSL Vifor intangibles and under-utilised property, plant and equipment.

Investors had already been warned. In May, CSL flagged around US$5 billion of impairments and cut its FY26 guidance.

Strip those exceptional costs out, however, and the picture looks considerably healthier. Underlying NPATA was US$3.1 billion, down just 2%, while revenue slipped 1% to US$15.8 billion — ahead of analyst expectations.

For investors, the result offered something potentially more important than a big profit: a reset year, a cleaner balance sheet and better-than-feared guidance.

CSL Behring remains the star performer. Its plasma division generated US$11.4 billion of revenue, while immunoglobulin revenue held steady at US$6.2 billion.

CSL Vifor grew revenue 3% to US$2.4 billion, although Seqirus remained a weak spot, with revenue falling 8% to US$2 billion.

Meanwhile, CSL’s transformation program delivered US$176 million in savings, and management committed US$1.5 billion to expand US plasma collection capacity.

The forecast that could send CSL shares higher

Here’s where the bull case gets interesting. CSL expects underlying NPAT to grow approximately 5% in FY27, ahead of consensus expectations of around 2%.

Behring is expected to deliver mid-single-digit growth, with immunoglobulins growing at a mid-to-high single-digit rate.

The major headache remains Vifor, where revenue is expected to plunge about 25% as iron generics enter the market.

Can CSL shares hit $200?

Not every broker is convinced.

Bell Potter retained its hold rating but lifted its target from $120 to $150. TradingView data shows 10 of 17 analysts have a hold rating, while seven rate CSL a buy or strong buy. The average 12-month target of $165.80 is below the current share price of around $168.30.

But the range is enormous. The most bullish forecasts see CSL climbing to $206.72, implying another 23% upside. At the other extreme, the lowest target is just $133.22, suggesting more than 20% downside.

Macquarie Group Ltd (ASX MQG) is the most bearish, with a neutral rating and target of just over $133. Of the leading brokers, UBS is the standout bull, targeting $181, while Morgan Stanley sees CSL reaching $172.

So, is $200 realistic? It is certainly possible, but the broker forecasts suggest investors shouldn’t mistake a spectacular rebound for a guaranteed recovery.

The post Could CSL shares really hit $200? Experts reveal their 12-month targets appeared first on The Motley Fool Australia.

More reading

• ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
• 3 ASX 200 stocks, including CSL, leaping 15% to 23% in this week’s sliding market
• 8 ASX shares just upgraded by the experts
• Why I’d buy CSL, Cochlear, and Pro Medicus shares
• CSL shares are flying higher. Is it too late to buy?

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has recommended CSL and Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

I love investing in Australia’s top shares when they’re trading at a low price. I think this describes the opportunity with the current Lovisa Holding Ltd (ASX: LOV) share price.

As the chart above shows, the Lovisa share price has dropped 46% since August 2025 and it’s down 15% from 7 August 2026.

After such a sizeable fall in a relatively small period of time, this could be the right time to consider one of the ASX’s leading retailers. Let’s look at why the jewellery retailer is so appealing.

Significant global growth plans

I think leading ASX growth shares need to have the potential to grow significantly in size today to unlock strong shareholder returns.

Lovisa already has around 1,100 global stores, but I think it can add significantly more. At the end of the FY26 half-year result, 219 of its global network was in Australia and New Zealand, with another 237 in the US.

It also has at least one store in Singapore, Malaysia, Hong Kong, Taiwan, China, Vietnam, South Africa, Namibia, Botswana, Zambia, the UK, Ireland, Spain, France, Germany, Belgium, Belgium, the Netherlands, Austria, Luxembourg, Switzerland, Poland, Italy, Hungary, Romania, UAE, USA, Canada, Mexico, a franchise in the Middle East and Africa, and a franchise in South America.

As you can see, it’s in numerous markets and this allows it to choose where to invest for new stores and earn the best return. The global network makes it one of Australia’s top shares, in my opinion.

Its expanding store count is a key growth tailwind. In HY26, the company reported its store count rose 15.5%. Combine that with positive comparable sales growth, and you’ve got a great revenue growth story.

In HY26, the company reported that Lovisa achieved revenue growth of 22.7%, with comparable sales growth of 2.2%.

Lovisa has also launched a new business called Jewells in the UK, which could add to earnings in the coming years.

Rapidly rising profit

The business is investing a fair amount into expanding its store network each year, yet its profit is also growing at an impressive pace, which is driving the underlying value of one of Australia’s top shares.

Lovisa reported that, excluding Jewells, operating profit (EBIT) grew 20.4% to $109.1 million and net profit grew 21.5% to $69.6 million.

I think if any business can grow its earnings regularly by more than 20% per year, then its intrinsic value will compound strongly.

As the business becomes larger, I think scale benefits will continue to strengthen, and this should help its profit margins improve.

Compelling valuation for one of Australia’s top shares

According to the forecast on Commsec, the Lovisa share price is valued at 28x FY26’s estimated earnings, with projections that earnings per share (EPS) could climb by another 27% in FY27.

I think the Lovisa share price is undervalued for how much its store network could increase in the coming years. At the current valuation, I think it’s one of Australia’s top share opportunities, though there could be volatility over certain periods.

The post A rare buying opportunity in 1 of Australia’s top shares? appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation to target a $5,500 monthly passive income?
• 7 ASX 200 shares downgraded by the experts this week
• 2 top ASX shares to buy and hold for the next decade
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Lovisa. The Motley Fool Australia has recommended Lovisa. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Deciding which ASX shares are buys and which ones are sells can be difficult. 

To help you figure things out, let’s look at three ASX shares that experts are tipping as sells this week, courtesy of The Bull. 

Here’s what they are saying:

CAR Group Ltd (ASX: CAR)

The team at Alto Capital is bearish on auto listings company CAR Group.

While it was pleased with its performance in FY 2026, it isn’t a fan of its valuation and believes the risk-reward is unfavourable for investors. It said:

CAR Group operates leading digital automotive markets in Australia and internationally. It delivered another strong result in fiscal year 2026. Reported revenue of $A1.253 billion was up 6 per cent on the prior corresponding period. Reported net profit after tax of $A314 million was up 14 per cent. International operations continue to generate attractive long term growth and management expects further revenue growth in fiscal year 2027. 

However, the company’s strong operating performance is increasingly reflected in its valuation, which requires sustained double digit growth and continuing successful international execution. In our view, the risk-reward balance in response to valuation supports a lighten recommendation.

Commonwealth Bank of Australia (ASX: CBA)

Red Leaf Securities has named CBA shares as a sell this week. While it acknowledges that CBA deserves to trade at a premium to peers, it believes a substantial re-rating leaves little room for disappointment. 

As a result, Red Leaf thinks investors should consider taking profit and focusing on areas with more reasonable valuations. It said:

CBA shares deserves to trade at a premium given its dominant retail franchise, strong technology platform, solid deposit base and consistent execution. However, Australian banking remains a mature industry, with intense competition across mortgages and deposits limiting the potential for outsized earnings growth. 

At a premium valuation, investors are paying a higher price for quality, leaving little room for disappointment. After a substantial re-rating, investors may be better served taking some profits and reallocating capital towards businesses offering stronger growth at more reasonable valuations.

Westpac Banking Corp (ASX: WBC)

The team at Red Leaf has also named Westpac shares as a sell this week.

It highlights the increasingly competitive environment as a reason to be cautious, especially given its valuation. It commented:

The bank remains well capitalised and continues to generate solid earnings, but the operating environment is becoming increasingly competitive. Mortgage pricing is aggressive, deposit competition remains intense and the scope for sustained margin expansion appears limited. Westpac’s dividend remains attractive, but investors should also consider opportunity cost. We believe there are more compelling opportunities on the ASX, which offer stronger structural growth or more attractive valuations.

The post Experts name CBA and these ASX shares as sells today appeared first on The Motley Fool Australia.

More reading

• How much do you need invested in ASX dividend shares to replace a $90,000 salary?
• 5 things Warren Buffett looks for before buying ASX shares
• 3 reasons to buy CBA shares following its results
• Want income for life? Here’s how I’d build an ASX dividend portfolio
• How much is needed in superannuation for $1500 in weekly passive income?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended CAR Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.